Floatz logo

Ad-Rts-Hil-12

Diffuse Intrinsic Pontine Glioma

Alaunos TherapeuticsPhase 1/2Dormant
C
37/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
22/ 100
Competitive Position
81/ 100

Competitive context

28 Active assets in the Diffuse Intrinsic Pontine Glioma cohort.

Asset / SponsorPhaseRating
Irinotecan
Actuate Therapeutics Inc.
Phase 2BB
(+)-VINCRISTINE
Julie Krystal
Phase 2B
Valproic Acid
University of Göttingen
Phase 3B
ETOPOSIDE
Theodore S. Johnson
Phase 2B
Everolimus
Nationwide Children's Hospital
Phase 2B

View all 42 →

Same molecule, other indications

Ad-Rts-Hil-12 is also rated in:

breast cancerDormant
CC
Indicative ·
44 / 100
View asset →
glioblastomaDormant
CC
Indicative ·
42 / 100
View asset →
brain neoplasmDormant
C
Indicative ·
37 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →